Mangalam Drugs & Organics Ltd
Company Profile
Business description
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
Contact
P. D'Mello Road
Rupam Building, 3rd Floor, No. 239
Near General Post Office
MumbaiMH400001
INDT: +91 2222616200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
480
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,321.10 | 10.80 | -0.12% |
CAC 40 | 8,258.86 | 52.79 | 0.64% |
DAX 40 | 24,330.03 | 71.23 | 0.29% |
Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
FTSE 100 | 9,426.99 | 23.42 | 0.25% |
HKSE | 25,738.08 | 289.47 | -1.11% |
NASDAQ | 22,953.67 | 36.88 | -0.16% |
Nikkei 225 | 49,347.08 | 31.02 | 0.06% |
NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
S&P 500 | 6,735.35 | 0.22 | 0.00% |
S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
SSE Composite Index | 3,907.96 | 8.37 | -0.21% |